- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 15:29 | Dogwood Therapeutics Announces FDA Acceptance Of IND Application For SP16 | 1 | RTTNews | ||
| 15:18 | Dogwood Therapeutics receives FDA clearance for SP16 pain trial | 2 | Investing.com | ||
| 15:06 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy | 94 | GlobeNewswire (Europe) | Dogwood licensed SP16 to treat cancer-related pain from partner and regulatory sponsor Serpin Pharma The SP16 Phase 1b trial fully funded by the National Cancer Institute; Patient enrollment expected... ► Artikel lesen | |
| 26.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 18.03. | Dogwood Therapeutics, Inc. - 10-K, Annual Report | 2 | SEC Filings | ||
| 18.03. | Virios Therapeutics GAAP EPS of -$0.26 | 1 | Seeking Alpha | ||
| 18.03. | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results | 289 | GlobeNewswire (Europe) | ATLANTA, March 18, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the "Company"), a development-stage biotechnology company developing new medicines to treat pain and neuropathy... ► Artikel lesen | |
| 12.03. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| DOGWOOD THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 13.01. | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 12.01. | Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron Through Phase 2b Development | 150 | GlobeNewswire (Europe) | Pricing of $12.5 Million Registered Direct Offering & Concurrent Private Placement Offerings priced at-the-market under Nasdaq rules ALPHARETTA, Ga., Jan. 12, 2026 (GLOBE NEWSWIRE) -- Dogwood Therapeutics... ► Artikel lesen | |
| 08.01. | Dogwood Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 22.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain | 360 | GlobeNewswire (Europe) | - Halneuron- treated patients separating from placebo on pain improvement assessment; Company expects top-line results availability in Q3 2026 - - The overall study dropout rate of ~4.4% is far below... ► Artikel lesen | |
| 02.12.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Files New Synthetic Halneuron Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045 | 279 | ACCESS Newswire | - New Composition of Matter Intellectual Property ("IP") Filing Centered on First-in-Class, Fully Synthetically Manufactured Halneuron-- New Synthetic Process to be Used for Phase 3 Development Provides... ► Artikel lesen | |
| 28.11.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.25 | Dogwood Therapeutics: Aktionäre machen Weg frei für Unternehmenszusammenschluss und neuen Eigenkapitalplan | 2 | Investing.com Deutsch | ||
| 21.11.25 | Dogwood Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 11.11.25 | Dogwood Therapeutics, Inc.: Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025 | 365 | ACCESS Newswire | - Continued low early termination rate among the first 80 study completers suggests Halneuron® and placebotreatmenthave been well tolerated ATLANTA, GEORGIA / ACCESS Newswire / November 11, 2025 / Dogwood... ► Artikel lesen | |
| 07.11.25 | Dogwood Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 06.11.25 | Virios Therapeutics GAAP EPS of -$8.20 misses by $6.62 | 2 | Seeking Alpha | ||
| 06.11.25 | Dogwood Therapeutics, Inc.: Dogwood Therapeutics Reports Third Quarter 2025 Financial Results | 393 | GlobeNewswire (Europe) | - Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured... ► Artikel lesen |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 84,90 | +1,74 % | BioNTech: Gute News - doch reicht das? | Nach dem heftigen Rücksetzer bei BioNTech, nachdem bekannt wurde, dass die beiden Gründer Ugur Sahin und Özlem Türeci bis spätestens Ende des Jahres das Unternehmen verlassen werden, arbeitet die Aktie... ► Artikel lesen | |
| EVOTEC | 5,545 | +2,88 % | Ihre wichtigsten Termine: Heute im Fokus der Analysten: FedEx, Volvo AB, Delta Air Lines, Evotec und Vestas | © Foto: picture alliance/AA/Guillaume Payen - picture alliance Gut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen... ► Artikel lesen | |
| VALNEVA | 2,647 | +0,42 % | SCHOCKMELDUNG bei Valneva: Könnte die Aktie jetzt komplett einbrechen? - Das sollten Sie jetzt wissen | ||
| AMGEN | 294,95 | -0,89 % | BeOne wins China approval for Amgen's lung cancer drug Imdelltra | ||
| NOVAVAX | 7,370 | +3,80 % | Activist investor revives campaign to overhaul Novavax board | ||
| BIOGEN | 151,40 | -0,22 % | Piper Sandler upgrades Biogen stock rating on acquisition strength | ||
| BIOFRONTERA | 2,660 | +3,91 % | BIOFRONTERA AG im Abwärtsmodus - ruhige Einordnung | ||
| BIONXT SOLUTIONS | 0,310 | +3,68 % | BioNxt beginnt mit der GMP-konformen Herstellung eines sublingualen Cladribin-Films in klinischer Qualität zur Behandlung von Multipler Sklerose (MS) | VANCOUVER, BC / ACCESS Newswire /
14. April 2026 / BioNxt Solutions Inc. ("BioNxt" oder das "Unternehmen") (CSE:BNXT)(OTCQB:BNXTF)(FWB:BXT), ein innovatives
Biowissenschaftsunternehmen, das... ► Artikel lesen | |
| MAINZ BIOMED | 0,556 | -8,38 % | Mainz Biomed BV: EPS übertrifft Schätzungen um 1,11 $ - Umsatz schlechter als erwartet | ||
| VIKING THERAPEUTICS | 30,200 | +0,17 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 12,400 | -0,96 % | Intellia Therapeutics, Inc. - 8-K, Current Report | ||
| TEMPUS AI | 47,175 | +12,29 % | Tempus AI Expands Collaboration With Gilead Sciences To Maximize Insights In Oncology Pipeline | FOSTER CITY (dpa-AFX) - Healthcare technology company Tempus AI, Inc. (TEM) Thursday announced an expanded, multi-year collaboration with Gilead Sciences, Inc. (GILD) to build and advance its... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,360 | -1,91 % | Defence Therapeutics Inc.: Defence Therapeutics Announces Warrant Terms Amendment | Montreal, Quebec--(Newsfile Corp. - March 20, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 8,038 | -1,95 % | BioCryst Pharmaceuticals, Inc.: BioCryst to Report First Quarter 2026 Financial Results on May 6 | ||
| NUREXONE BIOLOGIC | 0,418 | +2,45 % | Strategische Weichenstellung im Exosomenmarkt |
DOGWOOD THERAPEUTICS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -8,38 % bei einem Aktienkurs von 1,640 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu DOGWOOD THERAPEUTICS INC finden Sie auf Wallstreet Online.